PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23484006-5	2013	We therefore analyzed the effects of the c-MET- and VEGFR2 tyrosine kinase inhibitor cabozantinib (XL184, Exelixis) on c-MET positive orthotopic E98 glioblastoma xenografts, which routinely present with angiogenesis-dependent areas of tumor growth, as well as diffuse infiltrative growth.	cabozantinib	85-97	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	119-124	
23484006-6	2013	In in vitro cultures of E98 cells, cabozantinib effectively inhibited c-MET phosphorylation, concomitant with inhibitory effects on AKT and ERK1/2 phosphorylation, and cell proliferation and migration.	cabozantinib	35-47	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	70-75	
23484006-6	2013	In in vitro cultures of E98 cells, cabozantinib effectively inhibited c-MET phosphorylation, concomitant with inhibitory effects on AKT and ERK1/2 phosphorylation, and cell proliferation and migration.	cabozantinib	35-47	AKT serine/threonine kinase 1	Homo sapiens	132-135	
23484006-6	2013	In in vitro cultures of E98 cells, cabozantinib effectively inhibited c-MET phosphorylation, concomitant with inhibitory effects on AKT and ERK1/2 phosphorylation, and cell proliferation and migration.	cabozantinib	35-47	mitogen-activated protein kinase 3	Homo sapiens	140-146	
23484006-11	2013	Of importance, in contrast to the results from in vitro experiments, in vivo blockade of c-MET activation was incomplete, possibly due to multiple factors including restoration of the blood-brain barrier resulting from cabozantinib-induced VEGFR2 inhibition.	cabozantinib	219-231	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	89-94	
23484006-11	2013	Of importance, in contrast to the results from in vitro experiments, in vivo blockade of c-MET activation was incomplete, possibly due to multiple factors including restoration of the blood-brain barrier resulting from cabozantinib-induced VEGFR2 inhibition.	cabozantinib	219-231	kinase insert domain receptor	Homo sapiens	240-246	
23484006-12	2013	In conclusion, cabozantinib is a promising therapy for c-MET positive glioma, but improving delivery of the drug to the tumor and/or the surrounding tissue may be needed for full activity.	cabozantinib	15-27	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	55-60